Clinical Trial Update: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tarlatamab and ZL-1310, with or without anti-PD-L1, in small cell lung cancer; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anti-PD-L1 (PD-L1 inhibitor)
• Tarlatamab
• ZL-1310

Snippet

Sponsor: Amgen | Conditions: Small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING